Vanda Pharmaceuticals Inc. VNDA announced that its board of directors has unanimously rejected a potential acquisition bid by ...

In the past week, the company’s stock lost 51.2%. This downside came after management ... Ligand Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters. On average, LGND’s four ...

On average, LGND’s four-quarter earnings surprise was 84.81%. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway.

The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Ligand (LGND). While the effectiveness of ... revisions might translate into an upside in the stock.

Earnings of LGND beat estimates in each of the trailing ... Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it.

Aptevo Therapeutics APVO is a clinical-stage pharmaceutical company focused on developing novel therapies targeting cancer indications.In the past week, the company’s stock lost 79.0%. This downside ...